(Reuters) - Zogenix Inc’s experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, more than doubling the value of its shares and hurting those of peer GW Pharmaceuticals . In …
I wrote in August that Zogenix was a biotech stock that could soar in September. And it did. Zogenix stock more than doubled on Friday after announcing very good results from a late-stage study of experimental drug ZX008 in treating …
Sept 29 (Reuters) - Zogenix Inc's experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, putting it on track to request regulatory approval next year and more than tripling …
On Friday, shares of pharmaceutical company Zogenix Inc. ZGNX are skyrocketing, and as of 1:05 PM EST, the stock is trading up over 171% to $34.90 per share. ZGNX closed the day on Thursday at $12.88 per share, meaning the small …
Zogenix Inc. (NASDAQ: ZGNX) has been a controversial small cap drug stock, with its abuse-deterrent Zohydro being at front and center. Now that the company has submitted its supplemental new drug application (sNDA) with the U.S. …
If you want a Stock Review on IMNP, ZGNX, SHPG, or ABBV then come over to http://dailystocktracker.com/register/ …
Investors in Zogenix, Inc. ZGNX need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 20, 2017 $2 Put had some of the highest implied volatility of all equity options today. What is …